Erin Duffy, PHD
Chief of Research & Development
Erin Duffy, Ph. D., comes to CARB-X with 17+ years of drug-discovery and problem-solving experience in the antibiotic arena. She joined then Rib-X Pharmaceuticals (now Melinta Therapeutics) as it was nucleating in New Haven, Connecticut, where in increasing roles she helped to build and sustain a team of researchers that translated the company’s scientific platform into next-generation and novel antibiotics that target the ribosome. Her team’s most recent achievements include the de novo design and optimization of a completely new class of antibiotics, the pyrrolocytosines, which were supported in part by CARB-X. When Melinta made the decision in March of 2019 to cease research operations, she left the company as the EVP, Chief Scientific Officer and site head of New Haven (the research site). Prior to Rib-X, Erin was the Associate Director of Innovative Discovery Technologies at Achillion Pharmaceuticals: she was responsible for building the structure and computational teams and platform for their nascent antiviral efforts. She began her industrial career at Pfizer Central Research, in Groton, Connecticut, where she joined a team of computational and structural drug designers in multiple therapeutic areas. Erin was trained formally at Yale University, where she became a physical-organic chemist focused on defining computationally how small molecules interact and react in the group of Professor William L. Jorgensen. She expanded her experience to large molecules under the mentorship of Professor Axel Brunger, whose group at Yale was transitioning to a mix of computational and laboratory structural biology.